Form 8-K - Current report:
SEC Accession No. 0000950170-25-070905
Filing Date
2025-05-14
Accepted
2025-05-14 07:15:09
Documents
13
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K verv-20250514.htm   iXBRL 8-K 50627
2 EX-99.1 verv-ex99_1.htm EX-99.1 138334
3 GRAPHIC img74140242_0.jpg GRAPHIC 2993
  Complete submission text file 0000950170-25-070905.txt   329964

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT verv-20250514.xsd EX-101.SCH 31928
15 EXTRACTED XBRL INSTANCE DOCUMENT verv-20250514_htm.xml XML 4710
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40489 | Film No.: 25942627
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)